Skip to main
FHTX

Foghorn Therapeutics (FHTX) Stock Forecast & Price Target

Foghorn Therapeutics (FHTX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Foghorn Therapeutics is a promising biotechnology company with a strong focus on developing innovative treatments for cancer by targeting specific proteins. Their partnerships and successful preclinical research showcase their potential for success. With a strong team and a growing pipeline, Foghorn Therapeutics is poised for growth and success in the biotech industry.

Bears say

Foghorn Therapeutics is currently facing several fundamental risks that could negatively impact its stock performance. These include upcoming milestones relating to its flagship program FHD-909, a lack of head-to-head preclinical data comparing FHD-909 against other SMARCA2 targeted molecules, and commercialization and pricing risk given increasing competition in the precision therapeutics biotechnology space. Additionally, the company is reliant on access to capital and may require additional funding through equity offerings, which could dilute shareholder value and negatively impact the stock price. Despite the potential for combination approaches with a SMARCA2 targeted therapy, data from rivals like Prelude suggest significant safety concerns and potentially limited efficacy of these drugs, presenting a further hurdle for the company to overcome. Overall, these fundamental risks lead to a negative outlook on Foghorn Therapeutics and its stock.

Foghorn Therapeutics (FHTX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Foghorn Therapeutics (FHTX) Forecast

Analysts have given Foghorn Therapeutics (FHTX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Foghorn Therapeutics (FHTX) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Foghorn Therapeutics (FHTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.